JA Lust

1.2k total citations
13 papers, 917 citations indexed

About

JA Lust is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, JA Lust has authored 13 papers receiving a total of 917 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Genetics and 4 papers in Oncology. Recurrent topics in JA Lust's work include Multiple Myeloma Research and Treatments (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). JA Lust is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). JA Lust collaborates with scholars based in United States and Ireland. JA Lust's co-authors include PR Greipp, CY Li, RL Phyliky, Ayalew Tefferi, TE Witzig, RA Kyle, JA Katzmann, W. Michael O’Fallon, MA Gertz and O'Fallon Wm and has published in prestigious journals such as Blood, Leukemia and Haematologica.

In The Last Decade

JA Lust

12 papers receiving 896 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
JA Lust 599 370 347 346 241 13 917
Alfonso García de Coca 657 1.1× 309 0.8× 552 1.6× 346 1.0× 157 0.7× 47 984
Josefina Galende 635 1.1× 329 0.9× 469 1.4× 292 0.8× 175 0.7× 34 893
Guillermo Martín–Núñez 572 1.0× 248 0.7× 416 1.2× 289 0.8× 168 0.7× 26 822
M Tribalto 1.0k 1.7× 515 1.4× 629 1.8× 237 0.7× 141 0.6× 47 1.3k
TE Witzig 502 0.8× 307 0.8× 322 0.9× 232 0.7× 221 0.9× 13 795
Danielle Pineau 557 0.9× 297 0.8× 354 1.0× 294 0.8× 227 0.9× 19 860
Enrico Montefusco 985 1.6× 250 0.7× 273 0.8× 782 2.3× 199 0.8× 68 1.4k
Lisa Pleyer 435 0.7× 248 0.7× 369 1.1× 309 0.9× 204 0.8× 53 947
HM Kantarjian 879 1.5× 455 1.2× 358 1.0× 822 2.4× 237 1.0× 30 1.6k
Nathalie Grardel 848 1.4× 160 0.4× 322 0.9× 591 1.7× 180 0.7× 40 1.3k

Countries citing papers authored by JA Lust

Since Specialization
Citations

This map shows the geographic impact of JA Lust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JA Lust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JA Lust more than expected).

Fields of papers citing papers by JA Lust

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JA Lust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JA Lust. The network helps show where JA Lust may publish in the future.

Co-authorship network of co-authors of JA Lust

This figure shows the co-authorship network connecting the top 25 collaborators of JA Lust. A scholar is included among the top collaborators of JA Lust based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JA Lust. JA Lust is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Muchtar, Eli, Angela Dispenzieri, Shaji Kumar, et al.. (2016). Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 101(9). 1102–1109. 7 indexed citations
2.
Leung, Nelson, Siobhán Glavey, Shaji Kumar, et al.. (2013). A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. Haematologica. 98(6). 988–992. 34 indexed citations
3.
Gertz, MA, MQ Lacy, Angela Dispenzieri, et al.. (2009). A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma. Clinical Lymphoma & Myeloma. 9. S76–S77. 1 indexed citations
4.
Kapoor, Prashant, RA Kyle, S. Vincent Rajkumar, et al.. (2009). A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies. Clinical Lymphoma & Myeloma. 9. S60–S60.
5.
Anderson, Kenneth C. & JA Lust. (1999). Clinical parameters for determining when and when not to treat essential thrombocythemia.. PubMed. 36(1 Suppl 2). 14–20. 50 indexed citations
7.
Witzig, T.E., MA Gertz, JA Lust, et al.. (1996). Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]. Blood. 88(5). 1780–1787. 86 indexed citations
8.
Witzig, TE, MA Gertz, JA Lust, et al.. (1996). Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]. Blood. 88(5). 1780–1787. 81 indexed citations
9.
Garton, John P., MA Gertz, Thomas E. Witzig, et al.. (1995). Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.. PubMed. 155(19). 2069–74. 63 indexed citations
13.
Greipp, PR, JA Lust, W. Michael O’Fallon, et al.. (1993). Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]. Blood. 81(12). 3382–3387. 241 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026